---
title: "Apyx Medical study: Renuvion with liposuction shows higher patient satisfaction, lower revision and abdominoplasty rates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414686.md"
description: "Apyx Medical announced a study indicating that Renuvion combined with liposuction enhances patient satisfaction regarding abdominal appearance while significantly lowering revision and abdominoplasty rates. The study of 113 patients revealed a Body-Q score of 87.8 for those using Renuvion compared to 73.8 for those who did not (p=0.03). Additionally, satisfaction without abdominoplasty was higher at 68.8 versus 45.0 (p=0.039). Renuvion users had over 50% lower abdominoplasty rates (30.0% vs. 67.1%) and lower revision rates (12.0% vs. 37.5%; p=0.038), with comparable complication rates between groups."
datetime: "2026-05-14T12:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414686.md)
  - [en](https://longbridge.com/en/news/286414686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414686.md)
---

# Apyx Medical study: Renuvion with liposuction shows higher patient satisfaction, lower revision and abdominoplasty rates

**Apyx Medical announced a retrospective study showing Renuvion added to liposuction improved patient-reported abdominal appearance and reduced revision and abdominoplasty rates.**

**Key Highlights:**

-   Study of 113 patients found higher satisfaction with reduced excess skin (Body‑Q 87.8 vs. 73.8; p=0.03).
-   Among patients without abdominoplasty, abdominal satisfaction was higher with Renuvion (68.8 vs. 45.0; p=0.039).
-   Abdominoplasty rates were \>50% lower with Renuvion (30.0% vs. 67.1%).
-   Revision rates were significantly lower with Renuvion (12.0% vs. 37.5%; p=0.038).
-   Complication rates were comparable between groups (2.5% vs. 2.7%), indicating no increase in adverse events.

Original SEC Filing: Apyx Medical Corp \[ APYX \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APYX.US](https://longbridge.com/en/quote/APYX.US.md)

## Related News & Research

- [The magnificent seven dominated the last decade. Could MANGOS lead the next?](https://longbridge.com/en/news/294584648.md)
- [iOS 27: Tone Down Liquid Glass Transparency](https://longbridge.com/en/news/294355625.md)
- [Naspers says South Africa must build AI governance capability to attract investment](https://longbridge.com/en/news/294650102.md)
- [The CEO behind this AI companion says its 'little aliens' are popular with a surprising demographic](https://longbridge.com/en/news/294180693.md)
- [Fed Meeting Prediction Market Preview: What Will Kevin Warsh Say?](https://longbridge.com/en/news/294217702.md)